5.96

6.24% +0.35

Sight Sciences Inc (SGHT)

Overview News Price History Option Chain Financials Why SGHT Down? Discussions Forecast

Sight Sciences Inc stock is currently priced at $5.96, with a 24-hour trading volume of 91,491. It has seen a +6.24% increased in the last 24 hours and a +13.96% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $5.67 pivot point. If it approaches the $6.20 resistance level, significant changes may occur.

Previous Close:

$5.61

Open:

$5.61

24h Volume:

91,491

Market Cap:

$296.49M

Revenue:

$81.06M

Net Income/Loss:

$-55.55M

P/E Ratio:

-4.0822

EPS:

-1.46

Net Cash Flow:

$-47.98M

1W Performance:

+12.88%

1M Performance:

+13.96%

6M Performance:

+227.47%

1Y Performance:

-40.64%

1D Range:

$5.595

$5.99

52W Range:

$1.04

$11.00

Sight Sciences Inc Stock (SGHT) Company Profile

Name

Sight Sciences Inc

Sector

Healthcare (1213)

Industry

Medical Devices (160)

Phone

877 266 1144

Address

4040 Campbell Avenue, Suite 100, Menlo Park

Employee

169

Twitter

Next Earnings Date

2024-05-02

Latest SEC Filings

SGHT's Discussions on Twitter

Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-12-23	Downgrade	BofA Securities	Neutral → Underperform
Sep-12-23	Downgrade	Piper Sandler	Overweight → Neutral
Sep-12-23	Downgrade	William Blair	Outperform → Mkt Perform
Aug-24-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-10-23	Downgrade	Citigroup	Buy → Neutral
Jan-06-23	Upgrade	Stifel	Hold → Buy
Oct-04-22	Initiated	Needham	Hold
Jul-26-22	Initiated	Stifel	Hold
Feb-03-22	Initiated	William Blair	Outperform
Jan-07-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight

View All

Sight Sciences Inc Stock (SGHT) Latest News

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

GlobeNewswire Inc.

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

GlobeNewswire Inc.

Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der Senkung des Augeninnendrucks als auch bei der Einnahme von Medikamenten zur Senkung des Augeninnendrucks über einen Zeitraum von 2 Jahren bei Patienten mit Glaukom bekannt

GlobeNewswire Inc.

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

GlobeNewswire Inc.

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

GlobeNewswire Inc.

Sight Sciences Inc Stock (SGHT) Financials Data

Sight Sciences Inc (SGHT) Revenue 2024

SGHT reported a revenue (TTM) of $81.06 million for the quarter ending December 31, 2023, a +13.63% rise year-over-year.

Sight Sciences Inc (SGHT) Net Income 2024

SGHT net income (TTM) was -$55.55 million for the quarter ending December 31, 2023, a +35.59% increase year-over-year.

Sight Sciences Inc (SGHT) Cash Flow 2024

SGHT recorded a free cash flow (TTM) of -$47.98 million for the quarter ending December 31, 2023, a +37.64% increase year-over-year.

Sight Sciences Inc (SGHT) Earnings per Share 2024

SGHT earnings per share (TTM) was -$1.14 for the quarter ending December 31, 2023, a +36.67% growth year-over-year.

Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.